what this node claims
Initial digest — MC3R
AlphaFold v6 prediction landed for **MC3R** (Melanocortin-3 receptor). UniProt accession: `P41968`. Lane: `metabolic`. Mean per-residue pLDDT: **83.87**. Off-target of MC4R agonists; selectivity matters.
vertical proof spine
evidence / risk instrument
39%
low debt pressure
29%
28%structuredebt
pLDDT pending
55%evidencethin
grade C
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, alphafold_metric, candidate, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence
- 0.6
- evidence refs
- 1
AlphaFold metrics visual
Confident backbone model
323 residues / min 25.95 / max 98.56 / source alphafold db
Very high
61.9%
200 residues / >=90
Confident
21.1%
68 residues / 70-89
Low
5.9%
19 residues / 50-69
Very low
11.1%
36 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 323 of 323 residues.
- residues 1-34 / mean 36.2
- residues 227-240 / mean 61.99
- residues 317-323 / mean 49.82
proof debt register
29%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.